

10 May 2019

Dear Option holder

Participation in Non-Renounceable Entitlement Offer

Analytica Limited (Company) today announced that it is conducting a capital raising via a non-renounceable pro-rata entitlement offer to raise up to approximately \$2.7 million (before offer costs) at an issue price of 0.5 cents per share.

To be eligible to participate in the Entitlement Offer, option holders with a registered address in Australia or New Zealand must:

1. confirm that they are eligible to exercise all or part of their options (i.e. their options have vested); and
2. exercise their options so that they are a shareholder of the Company on the record date of 7pm (Sydney time) Wednesday, 15 May 2019.

If your options have not yet vested and cannot be exercised to participate in the Entitlement Offer, this letter is provided to you as a formality under the ASX Listing Rules.

Yours sincerely

Dr Michael Monsour**Chairman**


For more information, please contact: investorrelations@analyticamedical.com

For more information about the PeriCoach System, visit: www.PeriCoach.com

For more information about Analytica, visit www.AnalyticaMedical.com

Follow us on:





About Analytica Limited

Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to a cloud database where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition. Strengthening of the pelvic floor muscles can also potentially improve sexual sensation or satisfaction and orgasm potential in some women.

PeriCoach has regulatory clearance for urinary incontinence in Australia and has CE mark and USFDA 510(k) clearance.

PeriCoach also has clearance in Australia, and CE Marking in Europe for the treatment of pelvic organ prolapse, a condition that affects up to 1 in 5 women during their lifetime.

The product is available for sale from pericoach.com in Australia, New Zealand, UK and Ireland, and the USA.